Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model

Anti-Cancer Drugs

Volumn 23, Issue 5, 2012, Pages 525-533

  Heravi, Mitra ^a,c   Tomic, Nada ^a,b,c   Liang, Liheng ^a,b,c   Devic, Slobodan ^a,b,c   Holmes, Joseph ^a,b,c   Deblois, François ^a,b,c   Radzioch, Danuta ^a   Muanza, Thierry ^b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

breast cancer; ionizing radiation; Sorafenib

Indexed keywords

LIPOCORTIN 5; SORAFENIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL CYCLE; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; FLOW CYTOMETRY; G2 PHASE; GAMMA RAYS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; PROTEIN KINASE INHIBITORS; PYRIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859635099     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834ea5b3     Document Type: Article

References (34)

1. Belka C, Camphausen KA. Why 'radiation oncology'. Radiat Oncol 2006; 1:1.
2. Torres-Roca JF, Stevens CW. Predicting response to clinical radiotherapy: past, present, and future directions. Cancer Control 2008; 15:151-156.
3. Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006; 6:876-885. (Pubitemid 44629899)
4. Hirbe A, Morgan EA, Uluckan O, Weilbaecher K. Skeletal complications of breast cancer therapies. Clin Cancer Res 2006; 12:6309s-6314s. (Pubitemid 44703809)
5. Munshi A. Breast cancer radiotherapy and cardiac risk: the 15-year paradox! J Cancer Res Ther 2007; 3:190-192. (Pubitemid 351264092)
6. Goldblatt EM, Lee WH. From bench to bedside: the growing use of translational research in cancer medicine. Am J Transl Res 2010; 2:1-18.
7. Sofou S. Radionuclide carriers for targeting of cancer. Int J Nanomed 2008; 3:181-199. (Pubitemid 352037851)
8. Wilson GD, Bentzen SM, Harari PM. Biologic basis for combining drugs with radiation. Semin Radiat Oncol 2006; 16:2-9. (Pubitemid 41832311)
9. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109. (Pubitemid 39331023)
10. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134. (Pubitemid 46089673)
11. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of Sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512. (Pubitemid 46630627)
12. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006; 95:581-586. (Pubitemid 44325897)
13. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
14. Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST, et al. Phase 2 open-label study of single-agent Sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009; 115:428-436.
15. Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med 2006; 38:200-211. (Pubitemid 43675585)
16. Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL, et al. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 2008; 39:1835-1843.
17. Longo R, Gasparini G. Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol 2007; 60:151-170. (Pubitemid 46742547)
18. Li M, Jendrossek V, Belka C. The role of PDGF in radiation oncology. Radiat Oncol 2007; 2:5.
19. Loriot Y, Mordant P, Dorvault N, De la motte Rouge T, Bourhis J, Soria JC, et al. BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation. Br J Cancer 2010; 103:347-353.
20. Zwolak P, Dudek AZ, Bodempudi VD, Nguyen J, Hebbel RP, Gallus NJ, et al. Local irradiation in combination with bevacizumab enhances radiation control of bone destruction and cancer-induced pain in a model of bone metastases. Int J Cancer 2008; 122:681-688. (Pubitemid 350308965)
21. Tomic N, Gosselin M, Wan JF, Saragovi U, Podgorsak EB, Evans M, et al. Verification of cell irradiation dose deposition using a radiochromic film. Phys Med Biol 2007; 52:3121-3131. (Pubitemid 46795251)
22. Jane EP, Premkumar DR, Pollack IF. Coadministration of Sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther 2006; 319:1070-1080.
23. KilWJ, Cerna D, BurganWE, Beam K, Carter D, Steeg PS, et al. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 2008; 14:931-938. (Pubitemid 351231178)
24. Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X, et al. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 2009; 15: 607-612.
25. Hall EJ. Radiobiology for the radiologist, 5th edn. Philadelphia and London: Lippincott Williams & Wilkins; 2000.
26. Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, et al. Cell cycle dependent and schedule-dependent antitumor effects of Sorafenib combined with radiation. Cancer Res 2007; 67:9443-9454. (Pubitemid 47535934)
27. Virostko J, Xie J, Hallahan DE, Arteaga CL, Gore JC, Manning HC. A molecular imaging paradigm to rapidly profile response to angiogenesis-directed therapy in small animals. Mol Imaging Biol 2009; 11:204-212.
28. Pysz MA, Foygel K, Rosenberg J, Gambhir SS, Schneider M, Willmann JK. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology 2010; 256: 519-527.
29. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 2010; 70:1544-1554.
30. Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010; 70:4151-4162.
31. Wilson GD. Radiation and the cell cycle, revisited. Cancer Metastasis Rev 2004; 23:209-225. (Pubitemid 38881807)
32. Suen AW, Galoforo S, Marples B, McGonagle M, Downing L, Martinez AA, et al. Sorafenib and radiation: a promising combination in colorectal cancer. Int J Radiat Oncol Biol Phys 2010; 78:213-220.
33. Hahn O, Stadler W. Sorafenib. Curr Opin Oncol 2006; 18:615-621. (Pubitemid 44427636)
34. Hainsworth JD, Ervin T, Friedman E, Priego V, Murphy PB, Clark BL, et al. Concurrent radiotherapy and temozolomide followed by temozolomide and Sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 2010; 116:3663-3669.